GeoMx® Immune Pathways Panel
Helping Your Research
Targeted Content for Cancer Biology
The GeoMx Immune Pathways Panel is designed for targeted profiling of the tumor, tumor microenvironment, and tumor immune status.
Profile up to 96 RNA targets with spatial resolution from a single tissue section using the GeoMx Digital Spatial Profiler (DSP).
How it Works
The Immune Pathways panel contains 84 targets plus controls designed for broad coverage of the tumor and tumor microenvironment. GeoMx RNA assays contain in situ hybridization (ISH) probes conjugated to unique DNA indexing-oligonucleotides via a UV-photocleavable linker. After region of interest (ROI) selection on GeoMx DSP and UV cleavage of the oligonucleotides, each DNA oligonucleotide is recognized by a unique Reporter probe that contains a fluorescent barcode. Reporter probes are imaged and counted by the nCounter® Analysis System to provide a direct, digital readout of spatially resolved RNA expression.
- Curated content designed for immuno-oncology research
- Includes tumor and tumor microenvironment coverage plus the Tumor Inflammation Signature (TIS)
- Pre-validated in multiplex format for use in human FFPE or fresh frozen tissue
- Compatible with RNAscope® and antibody morphology markers for tissue imaging
- Customizable with up to 10 additional targets of interest
- For use with nCounter readout and compatible with DSP Data Center
Curated Content for Immuno-Oncology
The GeoMx Immune Pathways panel is designed to profile key aspects of the tumor and tumor microenvironment biology.
- Profile the global immune response
- Assess microenvironment immune activity
- Quantify tumor reactivity
- Measure the 18-gene Tumor Inflammation Signature known to be associated with response to PD-1/PD-L1 inhibitor pathway blockade
Accompanying Morphology Marker Kits are available for tissue visualization and ROI selection.
Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler
Breast cancer is a heterogenous disease with variability in tumor cells and in the surrounding tumor microenvironment (TME). Understanding the molecular diversity in breast cancer is critical for improving prediction of therapeutic response and prognostication.
Spatially organized multicellular immune hubs in human colorectal cancer.
Immune responses to cancer are highly variable, with mismatch repair-deficient (MMRd) tumors exhibiting more anti-tumor immunity than mismatch repair-proficient (MMRp) tumors. To understand the rules governing these varied responses, we transcriptionally profiled 371,223 cells from colorectal tumors and adjacent normal tissues of 28 MMRp and 34 MMRd individuals.
Comparison between non-pulmonary Comparison between non-pulmonary and pulmonary immune responses in a HIV decedent who succumbed to COVID-19.
We read with interest the study by Manuel et al showing that chronic immunosuppression could protect against severe COVID-19 in liver transplant patients. 1 Despite increased comorbidities, COVID-19 in liver transplant patients was not more severe than in non-transplant cohorts.